US FDA adds 7th feather to Humira's cap with colitis OK
This article was originally published in Scrip
Executive Summary
US drug maker Abbott won the FDA's OK on 28 September to expand the labeling for the firm's anti-tumor necrosis factor (TNF) blocker Humira (adalimumab) to include treatment of moderate-to-severe ulcerative colitis (UC) in adults when immunosuppressant medicines, like corticosteroids, azathioprine and 6-mercaptopurine, have not worked.